APE1/Ref-1 enhances DNA binding activity of mutant p53 in a redox-dependent manner

Oncology Reports

Volumn 31, Issue 2, 2014, Pages 901-909

  Cun, Yanping ^a   Dai, Nan ^a   Li, Mengxia ^a   Xiong, Chengjie ^b   Zhang, Qinhong ^a   Sui, Jiangdong ^a   Qian, Chengyuan ^a   Wang, Dong ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b WUHAN GENERAL HOSPITAL OF GUANGZHOU COMMAND   (China)

Author keywords

APE1 Ref 1; Mutant p53; p53 DNA binding

Indexed keywords

MESSENGER RNA; MUTANT PROTEIN; PROTEIN P21; PROTEIN P53; REDOX EFFECTOR FACTOR 1;

ADULT; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CARCINOMA CELL; CONTROLLED STUDY; DNA BINDING; DNA SEQUENCE; DNA STRUCTURE; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM;

CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DISEASE PROGRESSION; DNA; DNA REPAIR; DNA-(APURINIC OR APYRIMIDINIC SITE) LYASE; DNA-BINDING PROTEINS; FEMALE; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MUTATION; OXIDATION-REDUCTION; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; RNA, MESSENGER; TRANSCRIPTIONAL ACTIVATION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84892380304     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2892     Document Type: Article

References (50)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Fleck O and Nielsen O: DNA repair. J Cell Sci 117: 515-517, 2004.
3. Evans AR, Limp-Foster M and Kelley MR: Going APE over ref-1. Mutat Res 461: 83-108, 2000.
4. Wang D, Xiang DB, Yang XQ, et al: APE1 overexpression is associated with cisplatin resistance in non-small cell lung cancer and targeted inhibition of APE1 enhances the activity of cisplatin in A549 cells. Lung Cancer 66: 298-304, 2009.
5. Koukourakis MI, Giatromanolaki A, Kakolyris S, et al: Nuclear expression of human apurinic/apyrimidinic endonuclease (HAP1/Ref-1) in head-and-neck cancer is associated with resistance to chemoradiotherapy and poor outcome. Int J Radiat Oncol Biol Phys 50: 27-36, 2001.
6. Wang D, Luo M and Kelley MR: Human apurinic endonuclease 1 (APE1) expression and prognostic significance in osteosarcoma: enhanced sensitivity of osteosarcoma to DNA damaging agents using silencing RNA APE1 expression inhibition. Mol Cancer Ther 3: 679-686, 2004.
7. Xiang DB, Chen ZT, Wang D, et al: Chimeric adenoviral vector Ad5/F35-mediated APE1 siRNA enhances sensitivity of human colorectal cancer cells to radiotherapy in vitro and in vivo. Cancer Gene Ther 15: 625-635, 2008.
8. Di Maso V, Avellini C, Crocè LS, et al: Subcellular localization of APE1/Ref-1 in human hepatocellular carcinoma: possible prognostic significance. Mol Med 13: 89-96, 2007.
9. Puglisi F, Barbone F, Tell G, et al: Prognostic role of Ape/Ref-1 subcellular expression in stage I-III breast carcinomas. Oncol Rep 9: 11-17, 2002.
10. Helton ES and Chen X: p53 modulation of the DNA damage response. J Cell Biochem 100: 883-896, 2007.
11. Zurer I, Hofseth LJ, Cohen Y, et al: The role of p53 in base excision repair following genotoxic stress. Carcinogenesis 25: 11-19, 2004.
12. Strano S, Dell'Orso S, Di Agostino S, Fontemaggi G, Sacchi A and Blandino G: Mutant p53: an oncogenic transcription factor. Oncogene 26: 2212-2219, 2007.
13. McClendon AK, Dean JL, Ertel A, et al: RB and p53 cooperate to prevent liver tumorigenesis in response to tissue damage. Gastroenterology 141: 1439-1450, 2011.
14. Itoh T, Shiro T, Seki T, et al: Relationship between p53 overexpression and the proliferative activity in hepatocellular carcinoma. Int J Mol Med 6: 137-142, 2000.
15. Jayaraman L, Murthy KG, Zhu C, Curran T, Xanthoudakis S and Prives C: Identification of redox/repair protein Ref-1 as a potent activator of p53. Genes Dev 11: 558-570, 1997.
16. Hanson S, Kim E and Deppert W: Redox factor 1 (Ref-1) enhances specific DNA binding of p53 by promoting p53 tetramerization. Oncogene 24: 1641-1647, 2005.
17. Gohler T, Jager S, Warnecke G, Yasuda H, Kim E and Deppert W: Mutant p53 proteins bind DNA in a DNA structure-selective mode. Nucleic Acids Res 33: 1087-1100, 2005.
18. Gohler T, Reimann M, Cherny D, et al: Specific interaction of p53 with target binding sites is determined by DNA conformation and is regulated by the C-terminal domain. J Biol Chem 277: 41192-41203, 2002.
19. Hainaut P and Milner J: Redox modulation of p53 conformation and sequence-specific DNA binding in vitro. Cancer Res 53: 4469-4473, 1993.
20. Delphin C, Cahen P, Lawrence JJ and Baudier J: Characterization of baculovirus recombinant wild-type p53. Dimerization of p53 is required for high-affinity DNA binding and cysteine oxidation inhibits p53 DNA binding. Eur J Biochem 223: 683-692, 1994.
21. Yang S, Irani K, Heffron SE, Jurnak F and Meyskens FL Jr: Alterations in the expression of the apurinic/apyrimidinic endo nuclease-1/redox factor-1 (APE/Ref-1) in human melanoma and identification of the therapeutic potential of resveratrol as an APE/Ref-1 inhibitor. Mol Cancer Ther 4: 1923-1935, 2005.
22. Robertson KA, Bullock HA, Xu Y, et al: Altered expression of Ape1/ref-1 in germ cell tumors and overexpression in NT2 cells confers resistance to bleomycin and radiation. Cancer Res 61: 2220-2225, 2001.
23. Bobola MS, Blank A, Berger MS, Stevens BA and Silber JR: Apurinic/apyrimidinic endonuclease activity is elevated in human adult gliomas. Clin Cancer Res 7: 3510-3518, 2001.
24. Moore DH, Michael H, Tritt R, Parsons SH and Kelley MR: Alterations in the expression of the DNA repair/redox enzyme APE/ref-1 in epithelial ovarian cancers. Clin Cancer Res 6: 602-609, 2000.
25. Wilson DM III, Bennett RA, Marquis JC, Ansari P and Demple B: Trans-complementation by human apurinic endonuclease (Ape) of hypersensitivity to DNA damage and spontaneous mutator phenotype in apn1-yeast. Nucleic Acids Res 23: 5027-5033, 1995.
26. Hansen WK, Deutsch WA, Yacoub A, Xu Y, Williams DA and Kelley MR: Creation of a fully functional human chimeric DNA repair protein. Combining O6-methylguanine DNA methyl transferase (MGMT) and AP endonuclease (APE/redox effector factor 1 (Ref 1)) DNA repair proteins. J Biol Chem 273: 756-762, 1998.
27. Minisini AM, Di Loreto C, Mansutti M, et al: Topoisomerase IIalpha and APE/ref-1 are associated with pathologic response to primary anthracycline-based chemotherapy for breast cancer. Cancer Lett 224: 133-139, 2005.
28. Puglisi F, Aprile G, Minisini AM, et al: Prognostic significance of Ape1/ref-1 subcellular localization in non-small cell lung carcinomas. Anticancer Res 21: 4041-4049, 2001.
29. Zhang Y, Wang J, Xiang D, Wang D and Xin X: Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE1/Ref-1) in human ovarian cancer and indentification of the therapeutic potential of APE1/Ref-1 inhibitor. Int J Oncol 35: 1069-1079, 2009.
30. Muller PA, Vousden KH and Norman JC: p53 and its mutants in tumor cell migration and invasion. J Cell Biol 192: 209-218, 2011.
31. Norbury CJ and Zhivotovsky B: DNA damage-induced apoptosis. Oncogene 23: 2797-2808, 2004.
32. Yu Y, Li CY and Little JB: Abrogation of p53 function by HPV16 E6 gene delays apoptosis and enhances mutagenesis but does not alter radiosensitivity in TK6 human lymphoblast cells. Oncogene 14: 1661-1667, 1997.
33. Gaiddon C, Moorthy NC and Prives C: Ref-1 regulates the transactivation and pro-apoptotic functions of p53 in vivo. EMBO J 18: 5609-5621, 1999.
34. Couture C, Raybaud-Diogene H, Tetu B, et al: p53 and Ki-67 as markers of radioresistance in head and neck carcinoma. Cancer 94: 713-722, 2002.
35. Puisieux A, Ponchel F and Ozturk M: p53 as a growth suppressor gene in HBV-related hepatocellular carcinoma cells. Oncogene 8: 487-490, 1993.
36. Cadwell C and Zambetti GP: The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth. Gene 277: 15-30, 2001.
37. Demple B and Sung JS: Molecular and biological roles of Ape1 protein in mammalian base excision repair. DNA Repair 4: 1442-1449, 2005.
38. Kelley MR, Georgiadis MM and Fishel ML: APE1/Ref-1 role in redox signaling: translational applications of targeting the redox function of the DNA repair/redox protein APE1/Ref-1. Curr Mol Pharmacol 5: 36-53, 2012.
39. Tell G, Damante G, Caldwell D and Kelley MR: The intracellular localization of APE1/Ref-1: more than a passive phenomenon? Antioxid Redox Signal 7: 367-384, 2005.
40. Xanthoudakis S, Miao GG and Curran T: The redox and DNA-repair activities of Ref-1 are encoded by nonoverlapping domains. Proc Natl Acad Sci USA 91: 23-27, 1994.
41. Walker LJ, Robson CN, Black E, Gillespie D and Hickson ID: Identification of residues in the human DNA repair enzyme HAP1 (Ref-1) that are essential for redox regulation of Jun DNA binding. Mol Cell Biol 13: 5370-5376, 1993.
42. Anderson ME, Woelker B, Reed M, Wang P and Tegtmeyer P: Reciprocal interference between the sequence-specific core and nonspecific C-terminal DNA binding domains of p53: implications for regulation. Mol Cell Biol 17: 6255-6264, 1997.
43. Yakovleva T, Pramanik A, Terenius L, Ekstrom TJ and Bakalkin G: p53 latency - out of the blind alley. Trends Biochem Sci 27: 612-618, 2002.
44. Espinosa JM and Emerson BM: Transcriptional regulation by p53 through intrinsic DNA/chromatin binding and site-directed cofactor recruitment. Mol Cell 8: 57-69, 2001.
45. McKinney K and Prives C: Efficient specific DNA binding by p53 requires both its central and C-terminal domains as revealed by studies with high-mobility group 1 protein. Mol Cell Biol 22: 6797-6808, 2002.
46. Muller BF, Paulsen D and Deppert W: Specific binding of MAR/SAR DNA-elements by mutant p53. Oncogene 12: 1941-1952, 1996.
47. Lanyi A, Deb D, Seymour RC, Ludes-Meyers JH, Subler MA and Deb S: 'Gain of function' phenotype of tumor-derived mutant p53 requires the oligomerization/nonsequence-specific nucleic acid-binding domain. Oncogene 16: 3169-3176, 1998.
48. Frazier MW, He X, Wang J, Gu Z, Cleveland JL and Zambetti GP: Activation of c-myc gene expression by tumor-derived p53 mutants requires a discrete C-terminal domain. Mol Cell Biol 18: 3735-3743, 1998.
49. Ueno M, Masutani H, Arai RJ, et al: Thioredoxin-dependent redox regulation of p53-mediated p21 activation. J Biol Chem 274: 35809-35815, 1999.
50. Tan Z, Sankar R, Tu W, et al: Immunohistochemical study of p53-associated proteins in rat brain following lithium-pilocarpine status epilepticus. Brain Res 929: 129-138, 2002.